Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US8404813 | NA | Engineered anti-IL-23P19 antibodies |
Feb, 2031
(7 years from now) |
Ingredients: TILDRAKIZUMAB-ASMN
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic